Mark J. Ratain to Models, Biological
This is a "connection" page, showing publications Mark J. Ratain has written about Models, Biological.
Connection Strength
1.002
-
Models of excellence: improving oncology drug development. Clin Pharmacol Ther. 2012 Nov; 92(5):548-50.
Score: 0.266
-
Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther. 2008 Sep; 84(3):393-402.
Score: 0.194
-
Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling. Clin Transl Sci. 2016 Feb; 9(1):43-50.
Score: 0.083
-
Individualizing dosing of irinotecan. Clin Cancer Res. 2010 Jan 15; 16(2):371-2.
Score: 0.055
-
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol. 2002 May; 49(5):398-402.
Score: 0.032
-
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000 Jul; 18(14):2780-7.
Score: 0.028
-
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations. Cancer Chemother Pharmacol. 2000; 45(6):489-94.
Score: 0.027
-
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). J Clin Pharmacol. 2020 04; 60(4):444-452.
Score: 0.027
-
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS J. 2017 09; 19(5):1411-1423.
Score: 0.023
-
Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol. 1996 Jul; 14(7):2012-9.
Score: 0.021
-
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics. 1996 Feb; 6(1):93-101.
Score: 0.021
-
Pharmacodynamic modeling of prolonged administration of etoposide. Cancer Chemother Pharmacol. 1996; 39(1-2):61-6.
Score: 0.021
-
Limited sampling model for area under the concentration time curve of total topotecan. Clin Cancer Res. 1996 Jan; 2(1):43-6.
Score: 0.021
-
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol. 2014 Nov; 78(5):1005-13.
Score: 0.019
-
Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res. 1993 May 15; 53(10 Suppl):2304-8.
Score: 0.017
-
Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. Cancer Surv. 1993; 17:51-78.
Score: 0.017
-
Therapeutic relevance of pharmacokinetics and pharmacodynamics. Semin Oncol. 1992 Aug; 19(4 Suppl 11):8-13.
Score: 0.016
-
Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol. 1991 Aug; 9(8):1480-6.
Score: 0.015
-
Limited sampling models for doxorubicin pharmacokinetics. J Clin Oncol. 1991 May; 9(5):871-6.
Score: 0.015
-
Pharmacodynamics in cancer therapy. J Clin Oncol. 1990 Oct; 8(10):1739-53.
Score: 0.014
-
Dose-escalation models for combination phase I trials in oncology. Eur J Cancer. 2010 Nov; 46(16):2870-8.
Score: 0.014
-
Vascular endothelial growth factor pathway. Pharmacogenet Genomics. 2010 May; 20(5):346-9.
Score: 0.014
-
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos. 2010 Jan; 38(1):32-9.
Score: 0.014
-
Limited sampling model for vinblastine pharmacokinetics. Cancer Treat Rep. 1987 Oct; 71(10):935-9.
Score: 0.012
-
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol. 2007 Jan; 47(1):78-86.
Score: 0.011
-
A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther. 1995 Mar; 57(3):325-34.
Score: 0.005